MOLECULAR-GENETIC ANALYSIS DEMONSTRATES THAT MULTIPLE POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS OCCURRING IN ONE ANATOMIC SITE IN ASINGLE PATIENT REPRESENT DISTINCT PRIMARY LYMPHOID NEOPLASMS
A. Chadburn et al., MOLECULAR-GENETIC ANALYSIS DEMONSTRATES THAT MULTIPLE POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS OCCURRING IN ONE ANATOMIC SITE IN ASINGLE PATIENT REPRESENT DISTINCT PRIMARY LYMPHOID NEOPLASMS, Cancer, 75(11), 1995, pp. 2747-2756
Background. Posttransplantation lymphoproliferative disorders (PT-LPDs
) are a clinicopathologically heterogeneous group of lymphoid prolifer
ations of varied clonal composition, the majority of which are associa
ted with Epstein-Barr virus (EBV) infection. The clonal content and cl
onal relatedness of 24 separate PT-LPD lesions occurring synchronously
in one organ in a single patient were investigated. Methods. Twenty-f
our separate PT-LPD lesions from the colon and mesentery of a 15-year-
old male, developing 4 months after cardiac transplantation, were stud
ied for clonality based on immunoglobulin heavy chain (IgH) gene rearr
angements for the presence, clonality, and type of EBV infection and f
or the presence of c-myc, ras, and p53 gene alterations. Southern blot
hybridization, polymerase chain reaction, and single strand conformat
ion polymorphism assays were employed. Results. All 24 lesions were hi
stologically similar (polymorphic B-cell lymphomas) but exhibited vari
ed clonality and were clonally distinct with respect to both IgH gene
rearrangements and EBV infection. All lesions were infected with EBV t
ype A. Structural alterations of oncogenes or tumor suppressor genes w
ere not identified. Conclusions. Separate PT-LPD lesions occurring syn
chronously in a single organ or patient may be clonally distinct, sugg
esting that they represent multiple distinct primary lymphoid prolifer
ations rather than metastatic disease as in conventional malignant lym
phomas. This may explain partially the rapid development in some patie
nts of a large PT-LPD tumor burden that may regress rapidly after redu
ction of immunosuppression.